Saturday, 31 October 2026European Markets

OREGE Stock Bearish By 18% In The Last 5 Sessions

Loading stream...

orege (orege.pa), a company listed on the cac 40 index, has recently experienced significant financial shifts. over the course of five trading sessions, orege saw an 18% drop, from eur0.68 to eur0.55. this decrease in value has occurred simultaneously with a larger upward trend on the cac 40. the cac 40, during this time, has had its index climb slightly by 1.02% to eur7,343.96.

orege's troubling market performance

orege specializes in designing and operating municipal and industrial sludge treatment solutions. despite this niche industry, its share price has been on a steady decline since its 52-week high of eur0.82. as of last friday, its shares closed at eur0.59, a concerning 28.05% drop from the peak point.

orege's financial difficulties

adding to the concern around orege's financial stability, the earnings per share (eps), a measure of profitability, fell to eur-0.12 over the past twelve months. this negative eps is indicative of the financial difficulties that the company is enduring. additionally, a subsequent drop in the share price only further underscores these issues.

orege's continued operations

despite these poor stock market results, orege continues to persist in its industry. the company offers services related to installation and commissioning, operator training, warranty extensions, maintenance support, and process line optimization. therefore, it is apparent that the organization is striving to improve its current standing.

investor considerations

as orege's stock endures this period of turbulence, it is critical for potential investors to be vigilant of any sudden shifts in value. before venturing into this investment, the associated risks must be considered, especially those tied to an organization with negative earnings. this consideration is particularly pertinent for those wishing to invest in markets that are currently downtrending.

more news about orege (orege.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com